Digitally signed by 3c3ee476-b218-4a53-b649-4cac02f082e9
DN: CN=3c3ee476-b218-4a53-b649-4cac02f082e9
Reason: I am the author of this document
Location:
Date: 2025-06-20 19:42:37

No: 001/2025/BC-MED

Hanoi, June 20, 2025

REPORT OF THE BOARD OF DIRECTORS ON ITS PERFORMANCE IN 2024 AND THE PROPOSED OPERATIONAL PLAN FOR 2025

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022;*
- *Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;*

The Board of Directors for the 2024–2029 term of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders the Report of the Board of Directors on our performance in 2024 and the proposed operational plan for 2025 with the following main contents:

I. 2024 PERFORMANCE RESULTS

1. Board of Directors Personnel Structure

No.	Member	Position	Date of Commencement/ Termination as BOD Member/ Independent BOD Member	
			Date of appointment	Date of dismissal
1	Tran Hoang Dung	BOD Chairman	26/06/2024	
2	Tran Xuan Dinh	BOD Member	26/06/2024	
3	Tran Nguyen Hoang An	BOD Member	26/06/2024	
4	Nguyen Thi Thuy	BOD Member	26/06/2024	
5	Thai Khac Minh	BOD Independent member	26/06/2024	
6	Doan Thi Hong Thuy	BOD Chairman		26/6/2024

7	Tran Hoang Dung	BOD Vice Chairman		26/6/2024
8	Le Hong Trung	BOD Member		26/6/2024
9	Nguyen Ngoc Tuyen	BOD Member		26/6/2024
10	Nguyen Tien Phong	BOD Member		26/6/2024
11	Nguyen Van Khai	BOD Member		26/6/2024
12	Do Van Tan	BOD Independent member		26/6/2024

The composition of the BOD ensures a balanced structure among executive members, non-executive members, and independent members in accordance with the Company's Charter and the Internal Corporate Governance Regulations.

2. Resolutions/Decisions of the Board of Directors

In 2024, the Board of Directors convened 12 meetings to deliberate and decide on various matters within its functions and authority, resulting in the issuance of 14 resolutions.

All members of the Board of Directors attended the meetings in full, with the participation of the Board of Supervisors.

3. Activities of the Board of Directors

In 2024, the BOD operated in accordance with its functions, duties, and authority as prescribed by the Law on Enterprises, the Company's Charter, and applicable laws. All BOD meetings were organized and conducted in compliance with legal regulations, the Charter, and the Company's internal rules and procedures.

- All BOD members actively participated in meetings and jointly provided timely guidance, contributing to the effective achievement of the targets set by the General Meeting of Shareholders' resolutions.
- 2024 marked the transition between the 2020–2024 and 2024–2029 terms. BOD members regularly exchanged information to implement the Company's strategic objectives and promptly adjust to each development phase.
- Tasks were assigned among BOD members, and Mr. Tran Hoang Dung was elected as Chairman of the BOD.
- Mr. Tran Xuan Dinh was appointed as the General Director.
- The BOD issued internal regulations on financial management, internal expenditure, and debt management to strengthen corporate governance and improve oversight and control over operations, minimizing risks in business activities.

- Cost control was enforced across all departments, with a focus on managing receivables and payables, ensuring credit safety, and reinforcing professional oversight to minimize technical errors in operations.
- All information related to the Company's business activities was disclosed in a timely and transparent manner.

Key Performance Indicators Achieved in 2024

No.	Indicator	Unit	Plan 2024	Actual 2024	% Actual/Plan 2024
I	**Industrial Production**				
1	**Plant cost**	**VND**	**278,729,761,000**	**297,475,347,000**	**106.7%**
	Plant No. 1	VND	70,749,851,000	83,127,899,000	117.5%
	Plant No. 2	VND	207,979,910,000	214,347,448,000	103.1%
2	**Production Output of the Two Plants**	**Product Unit**	**635,386,000**	**650,122,000**	**102.3%**
	Plant No. 1	Product Unit	86,413,000	103,395,000	119.7%
	Plant No. 2	Product Unit	548,973,000	546,727,000	99.6%
II	**Overall Company Results**				
1	**Total Revenue**	**VND**	**360,724,200,700**	**443,135,811,734**	**122.8%**
2	Total Cost of goods sold	VND	280,114,838,340	350,574,416,654	125.2%
3	Gross Profit	VND	80,609,362,360	92,561,395,080	114.8%
5	Financial Expenses	VND	7,500,000,000	5,882,463,007	78.4%
7	Selling Expenses	VND	8,800,000,000	7,956,365,486	90.4%
8	General and Administrative Expenses	VND	48,692,066,920	62,411,577,931	128.2%
III	**Earning before tax**	**VND**	**16,117,295,440**	**19,418,107,894**	**120.5%**

Indicator	2023	2024	% Change
Total Asset	555,242,708,304	503,755,172,939	-9.27%
Revenue	402,741,168,246	443,135,811,734	10.0%
Operating Profit	15,321,686,437	18,505,896,390	20.8%
Other Profit	(398,621,480)	912,211,504	328.8%
Earning before tax	14,923,064,957	19,418,107,894	30.1%
Net Profit	11,743,892,351	15,246,766,212	29.8%

1. Supervision Results of the Board of Directors over the General Director

The new-term Board of Directors dismissed Mr. Tran Hoang Dung from the position of General Director, appointed Mr. Tran Xuan Dinh as the new General Director, and restructured the Board of Management.

The BOD directed and supervised the operations of the BOM, promptly addressing matters within the BOD's authority.

The BOD's assessment: The BOM performed its assigned duties in accordance with the law, the Company's Charter, resolutions of the General Meeting of Shareholders (GMS), and resolutions/decisions of the BOD, specifically:

- The Board of Management submitted regular reports at BOD meetings and provided ad-hoc reports upon request whenever issues arose under the authority of the BOD or its Chairman, so that timely guidance and solutions could be given to support and facilitate the BOM's operations.

- Successfully organized the 2024 Annual General Meeting of Shareholders on June 26, 2024.

- Effectively implemented the key tasks and solutions in 2024 as directed by the Board of Directors:

+ The Board of Management was fully aware of both the opportunities and challenges, and thus operated the business flexibly. It issued internal regulations and decisions within the authority of the General Director to effectively manage all business activities, resulting in an earning before tax that exceeded the 2024 target by 20.5%.

+ The BOM intensified efforts in debt collection, reducing overall debt levels, especially overdue receivables. Cash flow planning was well-controlled to optimize financial costs and reduce bank interest expenses.

+ The BOM strictly managed production costs and office administration expenses. All procurement and investment activities were conducted in accordance with the Company's internal regulations and applicable laws.

2. Evaluation Results from the Independent Member on the Activities of the Board of Directors

As of December 31, 2024, the Company's BOD included two independent members. These members participated in 100% of the BOD's meetings and written consultations in 2024, and contributed valuable input to the Company's strategic direction and development.

Based on their assessment of the BOD's activities in 2024, the independent members concluded:

– BOD meetings were convened and conducted according to a clear schedule, with well-prepared documentation in accordance with regulations. The BOD operated effectively, making timely and appropriate decisions aligned with the Company's situation and market conditions. Meetings were held regularly, and important matters were thoroughly discussed and resolved by consensus.

– Development strategies, plans, and policies were implemented in line with the orientations approved by the General Meeting of Shareholders.

– The BOD placed strong emphasis on risk management to ensure stable and sustainable operations. Potential risks were identified and assessed carefully, with effective mitigation measures applied.

– The BOD fulfilled its assigned duties with high responsibility and professionalism, in strict compliance with laws, the Company's Charter, and ethical standards in business activities.

3. Remuneration and Salary Payment for the Board of Directors

The salary and remuneration for the Board of Directors were paid in accordance with the resolution of the 2024 Annual General Meeting of Shareholders *(The figures are reflected in the audited 2024 financial statements).*

4. Transactions with Related Parties

No.	Name	Related Party Relationship	NSH No. / Issue Date / Place of Issue	Head Office Address	Transaction Time

1	An Hy Pharmaceutical Company Limited	Related Party of Mr. Tran Hoang Dung – Chairman of the Board of Directors	Enterprise Registration Certificate No. 0309738339, issued on May 22, 2017 by the Department of Planning and Investment of Ho Chi Minh City	No. 506/15/34, 3/2 Street, Ward 14, District 10, Ho Chi Minh City	2024
2	Northern Medibros Medicine Joint Stock Company	Mr. Le Hong Trung and Mr. Nguyen Tien Phong (dismissed) were members of the Company's Board of Directors.	Enterprise Registration Certificate No. 0107575836, issued on September 25, 2016 by the Department of Planning and Investment of Hanoi City	No. 358 Giai Phong Street, Phuong Liet Ward, Thanh Xuan District, Hanoi City	2024
3	Medibros Central Regional Pharmaceutical Joint Stock Company	Mr. Nguyen Tien Phong (dismissed) was a member of the Company's Board of Directors.	Enterprise Registration Certificate No. 0401696994, issued on September 18, 2015 by the Department of Planning and Investment of Da Nang City	No. 512, 29/03 Street, Hoa Xuan Ward, Cam Le District, Da Nang City	2024

II.ORIENTATION AND OPERATION PLAN FOR 2025

The economic outlook for 2025 remains subject to significant volatility, with ongoing uncertainties related to geopolitical tensions, international tariff policies, and disruptions in global supply chains. Domestically, the pharmaceutical sector continues to face numerous administrative hurdles and regulatory changes that substantially affect production activities and product distribution.

Based on an assessment of current production capacity and market risk factors, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company proposes to submit the 2025 Business and Production Plan to the General Meeting of Shareholders as follows:

1. Business Plan for 2025:

No	Indicator	Unit	Amount
I	**Industrial Production**	**Product Unit**	**513,703,843**

1	Plant No.1	Product Unit	87,055,738
2	Plant No.2	Product Unit	426,648,105
II	**Total Revenue**	**VND**	**296,207,000,113**
III	**Cost of goods sold**	**VND**	**223,094,819,228**
IV	**Gross Profit**	**VND**	**73,112,180,885**
V	**Selling Expenses**	**VND**	**5,009,034,126**
VI	**Service Revenue**	**VND**	**3,700,000,000**
	Financial Expenses	VND	3,850,000,000
VII	**Administrative Expenses**	**VND**	**55,049,459,188**
VIII	**Earning before tax**	**VND**	**12,903,687,571**

2. Operational Orientation and Solutions:

- In 2025, the Board of Directors will continue holding regular quarterly meetings in accordance with regulations, as well as ad-hoc meetings and written consultations with BOD members to implement the Resolutions of the 2025 Annual General Meeting of Shareholders, address corporate governance matters, and direct the execution of 2025 tasks.
- Strengthen governance over economic targets and corporate management by organizing an efficient operating system and ensuring transparent control over key areas such as timely debt collection, company expenses, and capital utilization.
- Direct the Board of Management to focus on consolidating and expanding production at the Company's plants, based on scientifically and strategically positioning key products.
- Enhance conditions for R&D efforts, focusing on the development of high-value, knowledge-intensive products that offer economic efficiency, gradually replacing and improving strategic products.
- Improve digital management by accelerating digital transformation and applying artificial intelligence across all operational aspects of the Company.

This report presents the Board of Directors' assessment of its performance in 2024 and the proposed operational plan for 2025. The achievements in 2024 have laid a solid foundation for our continued confidence in the sustainable development of Mediplantex National Pharmaceutical Joint Stock Company. On behalf of the Board of Directors, I would like to

express my sincere thanks to the Board of Management and all company staff for their constant dedication and efforts toward the growth and success of Mediplantex. We also extend our heartfelt appreciation to our valued shareholders, investors, customers, and partners for your unwavering trust and continued support on the journey toward a prosperous and sustainable Mediplantex.

Sincerely!

Recipients:

- *BOD*
- *BOM*
- *Shareholders*
- *State Securities Commission*
- *Archived: Company Secretary*

ON BEHALF OF
THE BOARD OF DIRECTORS



Thai Khac Minh

No. 02/2025/BC-MED *Hanoi, June 20, 2025*

REPORT OF THE BOARD OF MANAGEMENT ON THE 2024 BUSINESS AND PRODUCTION RESULTS AND THE IMPLEMENTATION PLAN FOR 2025

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

In 2024, the global economy continued to face numerous challenges, marked by unpredictable developments and widespread instability. The pharmaceutical sector, in particular, was affected not only by international headwinds but also by certain domestic regulatory barriers, including circulars and decrees, which impacted business operations. In response to these circumstances, Mediplantex set a unified overarching objective, adopted flexible management strategies, and relied on a resilient and committed team of employees, all determined to overcome this challenging period together.

I. BUSINESS PERFORMANCE RESULTS IN 2024:

1. Favorable Factors during the Year:

- A reputable brand and good product quality trusted by partners.
- A leadership team with vision, dedication, and innovative thinking.
- A united, committed workforce with high professional skills.
- Consensus and support from the company's shareholders.

2. Challenges in Implementing the Business and Production Plan:

- Changes in the Drug Administration's regulatory policies caused prolonged delays in the issuance, renewal, and modification of marketing authorizations, exceeding the prescribed timelines. Frequent updates and additions to regulations on drug pricing dossiers required the company to devote significant time to documentation, resulting in a lack of valid registration numbers for production and sales.
- The domestic market for pharmaceuticals and health supplements has not seen significant recovery due to difficulties in implementing policies related to drug bidding in healthcare facilities.
- The organizational structure of the manufacturing plant and intermediary departments remained cumbersome and had not been streamlined. A large workforce involved in production led to high personnel management costs. Amid economic challenges, optimizing labor resources presented a major difficulty in balancing operational efficiency and cost.

- Volatile prices of raw materials, excipients, and packaging materials, along with disrupted supply chains due to price competition, forced the company to continuously seek and qualify alternative suppliers. This impacted production timelines and cost strategy planning.

3. Key Solutions and Core Tasks Implemented During the Year:

- The Board of Management carried out a restructuring to help the company operate more effectively, based on existing foundations of mission, vision, and strategic orientation. The workforce and working processes between units and departments were reorganized to match the company's production model.
- Implemented work plans appropriate to the actual situation and consistently aligned with the 2024 business plan, ensuring conformity with the company's development orientation.
- Strengthened Financial Risk Management:
  + Enhanced control over accounts receivable to minimize capital encroachment.
  + Improved capital turnover to optimize financial efficiency.
  + Prevented the emergence of bad debts and successfully recovered outstanding receivables.
- Improved Operational Efficiency in Production:
  + Strengthened quality control from raw material inputs to finished product outputs.
  + Organized efficient production management to prevent waste, reduce material consumption, and allocate labor rationally to lower production costs.
- Market Expansion and Product Diversification
  + Promoted research and development of new products in line with consumer trends.
  + Expanded distribution channels and partnered with strategic collaborators to increase market share.

4. Performance Indicators Achieved:

No.	Indicator	Unit	2024 Plan	2024 Actual Performance	% 2024 Actual Performance/ 2024 Plan
I	**Industrial Production**				
1	**Factory Cost**	**VND**	**278,729,761,000**	**297,475,347,000**	**106.7%**
	Plant No. 1	VND	70,749,851,000	83,127,899,000	117.5%
	Plant No. 2	VND	207,979,910,000	214,347,448,000	103.1%
2	**Production Output of the Two Plants**	**Unit of product**	**635,386,000**	**650,122,000**	**102.3%**
	Plant No. 1	Unit of product	86,413,000	103,395,000	119.7%
	Plant No. 2	Unit of product	548,973,000	546,727,000	99.6%
II	**Company-Wide Summary**				

1	Total Revenue	**VND**	**360,724,200,700**	**443,135,811,734**	**122.8%**
2	Total Cost of Goods Sold	VND	280,114,838,340	350,574,416,654	125.2%
3	Gross Profit	VND	80,609,362,360	92,561,395,080	114.8%
5	Financial Expenses	VND	7,500,000,000	5,882,463,007	78.4%
7	Selling Expenses	VND	8,800,000,000	7,956,365,486	90.4%
8	General and Administrative Expenses	VND	48,692,066,920	62,411,577,931	128.2%
III	**Profit Before Tax**	**VND**	**16,117,295,440**	**19,418,107,894**	**120.5%**

- In addition, the Board of Management directed a focused effort on research and development of new products, as well as the formulation of the company's strategic product portfolio, which has yielded the following positive outcomes:

No.	Indicator	Unit	2023	2024
1	New registration numbers granted	Product	18	23
2	Renewal registration numbers granted	Product	28	157
3	Health supplements and cosmetics newly registered	Product	2	09
4	Price declaration dossiers approved	Product	30	10
5	Approved changes, supplements, and updates	Product	76	192 (14 dossiers for manufacturer supplements)
6	Approved changes, supplements, and updates	Product		18
7	Implemented improvements to formulas and production processes	Product	17	05

5. Status of the Investment Project "Pharmaceutical Science and Technology Center and Application-based Pharmaceutical Manufacturing Plant meeting EU-GMP Standards":

5.1 Content:

- Amendment of the Enterprise Registration Certificate No. 0100108430 issued by the Hanoi Department of Planning and Investment, first issued on April 12, 2005, with the 20th amendment registered on January 3, 2025
- Adjustment of the project scale, specifically the production capacity:

- Increase in production volume of cephalosporin antibiotic tablets/granules/powders (nano products) from 100,000,000 units/year (equivalent to 50 tons/year) to 300,000,000 units/year (equivalent to 150 tons/year); Increase in production volume of cephalosporin antibiotic injections (nano-based products) from 20,000,000 units/year (equivalent to 5 tons/year) to 32,000,000 units/year (equivalent to 8 tons/year).

- Adjustment of total investment capital: Increase in total investment capital by 20% or more, resulting in a change in project investment scale (from VND 724 billion to VND 892 billion).
- Adjustment of implementation schedule:

- Phase 1:

+ Commencement of construction, implementation, acceptance, and completion of Office Building, Workshops B and C, and auxiliary works, and putting them into use: Q4/2020 – Q1/2026

+ Installation of machinery, equipment, and trial operation of Phase 1 workshops: Q1/2026 – Q2/2026

+ Commissioning and operational launch of Phase 1 facilities: Q3/2026.

- Phase 2:

+ Commencement of construction, implementation, acceptance, and completion of Workshop A, Workshop D, and Central Warehouse, and putting them into use: Q4/2025 – Q2/2027.

+ Installation of machinery, equipment, and trial operation of Phase 2 workshops: Q2/2027 – Q3/2027

+ Commissioning and operational launch of Phase 2 facilities: Q4/2027.

2. Outcome:

- The Hoa Lac Hi-Tech Park Management Board issued Decision No. 235/QĐ-CNCHL approving the adjustment of the investment policy (initial approval dated July 19, 2019; first amendment on November 27, 2024).

II. BUSINESS OPERATION ORIENTATION FOR 2025

1. Challenges and Difficulties in Implementing the 2025 Plan

The year 2025 is projected to remain challenging across various global economic sectors, with key obstacles as follows:

- Global Geopolitical Instability: Ongoing tensions in several regions (e.g., Europe, the Middle East) continue to disrupt global supply chains, posing significant challenges to the importation of raw materials, pharmaceutical excipients, and packaging essential for production.

- New Tariff Policies: Newly implemented trade and tariff regulations by various countries may cause exchange rate volatility, increase import costs, and elevate risks associated with export expansion, thereby impacting the company's international trade strategies.
- Currency Fluctuations: Unstable foreign exchange rates, particularly involving the USD and CNY, will likely increase the cost of imported inputs—which represent a significant proportion of product cost—thus putting pressure on profit margins, pricing strategies, and possibly disrupting raw material supply continuity.
- Regulatory Hurdles in the Pharmaceutical Sector: Persistent regulatory bottlenecks remain unresolved. Widespread inspections and audits by state regulatory authorities have adversely impacted market sentiment and directly affected pharmaceutical enterprises, resulting in short-term revenue declines.
- Delays in Product Registration: Core and newly developed products are facing difficulties and delays in obtaining marketing authorizations, significantly affecting revenue growth, output expansion, and efforts to attract new customers.

2. 2025 Production and Business Plan with Key Performance Indicators:

No.	INDICATOR	UNIT	VALUE
I	**Industrial Production**	**Unit of product**	**513,703,843**
1	Plant No. 1	Unit of product	87,055,738
2	Plant No. 2	Unit of product	426,648,105
II	**Total Sales Value**	**VND**	**296,207,000,113**
III	**Cost of Goods Sold**	**VND**	**223,094,819,228**
IV	**Total Gross Profit**	**VND**	**73,112,180,885**
V	**Total Selling Expenses**	**VND**	**5,009,034,126**
VI	**Revenue from Service Provision**	**VND**	**3,700,000,000**
	Financial Expenses	VND	3,850,000,000
VII	**Administrative Expenses**	**VND**	**55,049,459,188**
VIII	**Profit Before Tax**	**VND**	**12,903,687,571**

3. Operational Orientation:

- Continue implementing the streamlining restructuring project and deploying the ERP enterprise resource planning system with the aim of modernizing the management model, optimizing operational efficiency, and standardizing production and business processes in the direction of comprehensive digitalization.

- Continue seeking customers, expanding cooperation with domestic and international partners; maintain production volume with major customers; develop export markets through international trade promotion activities.
- Develop new products, conduct research to improve formulations and production processes of existing products. 2025 plan includes tasks related to research and development:

No.	Description	Unit	Quantity
1	Dossiers granted new marketing authorization numbers	Dossier	23
2	Dossiers registered for renewal	Dossier	10
3	Registration of dietary supplements and cosmetics	Dossier	8
4	Dossiers for modifications and supplements	Dossier	80
5	Implementation of new product manufacturing	Product	20
6	Improvement of manufacturing formulas and production procedures	Product	3

- Continue reviewing professional regulations, procedures, and technical guidelines to ensure full compliance with GMP, GSP, GDP requirements and corporate governance standards. Standardize products to ensure consistent product quality, and minimize violations or recalls due to quality issues.
- Manage production efficiently to avoid waste, reduce material consumption, and optimize labor utilization to lower production costs and enhance product competitiveness.
- Develop inventory and procurement plans with optimal quantities to benefit from suppliers' preferential policies, reduce input costs, and lower the budget for purchasing raw materials and packaging.
- Effectively implement financial solutions related to cash flow management, inventory, and outstanding debts; restructure loans to ensure adequate capital for production, business operations, and investment activities in 2025.

The above is the report of the Board of Management on the business performance in 2024 and the orientation for the implementation of the 2025 business plan.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval.

GENERAL DIRECTOR

Recipients:
- *BOD*
- *BOM*
- *Shareholders*
- *SSC*
- *Archived: Secretary*

Mai Nhat Thanh

No: 03/2025/BC-MED *Hanoi, June, 2025*

REPORT OF THE BOARD OF SUPERVISORS
ON ITS 2024 ACTIVITIES AND SUPERVISORY WORK, ALONG WITH THE PROPOSED PLAN FOR 2025

To: The General Meeting of Shareholders

- Pursuant to the Law on Enterprises and the Charter of Mediplantex National Pharmaceutical Joint Stock Company stipulating the functions and authority of the Board of Supervisors;

- Pursuant to the Resolution of the 2024 General Meeting of Shareholders and the Resolutions of the Board of Directors in 2024;

- Pursuant to the business performance results and the 2024 financial statements audited by AASC Auditing Firm Company Limited;

The Board of Supervisors (BOS) of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders (GMS) the report on its activities in 2024 and the proposed plan for 2025, with the following key contents:

I. Organization and Activities of the Board of Supervisors:

1. Personnel of the Board of Supervisors:

The Board of Supervisors consists of 3 members, including:

- Mr. Ho Ngoc Tuan : Head of the Board of Supervisors
- Ms. Ha Thi Bich Hanh : Member of the Board of Supervisors
- Ms. Do Ngoc Thuy : Member of the Board of Supervisors

2. Activities of the Board of Supervisors:

During the year, the Board of Supervisors fully performed its duties and responsibilities as assigned by the General Meeting of Shareholders, specifically overseeing, inspecting, and supervising the Company's governance, management, and business operations. The Board operated with a strong sense of responsibility, clearly delegated tasks to each member, and appointed representatives to attend meetings of the Board of Directors (BOD) and the Board of Management (BOM).

The Board of Supervisors maintained full and regular working relations with the BOD and the General Director in business operations, monitoring the Company's activities to ensure compliance with applicable laws. It also regularly exchanged

information with the BOD and General Director regarding the implementation of business plans and resolutions approved by the General Meeting of Shareholders.

Based on its functions and duties as stipulated by the Law on Enterprises, the Company's Charter, and the Regulations on Organization and Operation of the Board of Supervisors, the Board carried out the following activities during the year:

- Attended the Company's Annual General Meeting of Shareholders.
- Participated in regular and extraordinary meetings of the Board of Directors.
- Monitored financial and accounting activities, including review of the semi-annual and annual financial statements of the Company.
- Supervised the activities of the BOD and the Board of Management in accordance with the law and resolutions of the General Meeting of Shareholders.
- Oversaw the Company's information disclosure in compliance with legal regulations.
- Proposed the selection of an independent auditing firm to audit the Company's annual and semi-annual financial statements; assessed the financial statements before and after the audit.
- Provided input on the development of operating regulations for the Company by the BOD and the Board of Management.
- Cooperated with relevant departments to inspect and assess business operations.
- Held regular and extraordinary meetings of the Board of Supervisors to review, discuss, and evaluate the Company's performance.
- Performed other duties in accordance with the functions and responsibilities of the Board of Supervisors.

II. Evaluation by Task Group:

1. Evaluation by the BOS on the Activities of the BOD:

- Governance activities were carried out in accordance with the law, the Company's Charter, and the resolutions of the General Meeting of Shareholders.

- The BOD ensured transparency and openness in management, with a strategic focus on business development and efficiency.

- The BOD held regular meetings with clear agendas, documented minutes, and issued resolutions instructing the General Director to implement decisions. However, in the past period, the BOD was unable to organize meetings as regularly

planned due to the health condition of the Chairman. The BOS recommends that the BOD resume regular meetings as prescribed.

- During the year, the BOD amended, supplemented, and issued several regulations, documents, resolutions, and decisions, providing a structured, focused, and unified foundation for corporate governance.

2. Evaluation by the BOS on the General Director's Implementation of Resolutions of the GMS and the BOD:

- The General Director implemented various measures to strengthen financial management by controlling expenses, monitoring customer receivables, and managing operational activities in line with the objectives set by the General Meeting of Shareholders and the BOD.

- Took the initiative in executing the business plan, fully fulfilled obligations to the State and shareholders, and paid attention to employee welfare.

- Organized the year-end review conference to comprehensively evaluate business operations, identify limitations and shortcomings, and propose appropriate solutions and corrective actions.

- Focused on addressing internal weaknesses of the Company to improve operational efficiency and reduce costs.

- Regarding investment and co-investment projects that are behind schedule, the Board of Supervisors submitted recommendations to the BOD and the Board of Management, requesting a thorough review to ensure legal compliance and investment efficiency.

- For several resolutions issued by the BOD that have not yet been implemented, the Board of Supervisors recommends that the BOM promptly report back to the BOD.

III. Review and Evaluation of Financial Statements:

1. Preparation and Audit of Financial Statements:

- The Company's financial statements were prepared in accordance with current Vietnamese Accounting Standards. The annual and semi-annual financial statements were audited by AASC Auditing Firm Company Limited.

- The Board of Supervisors reviewed the financial statements and concurred with the reported business results. According to the audit opinion provided by AASC, the Company's financial statements were presented fairly, accurately, completely, and clearly, and were in compliance with applicable accounting standards.

However, the auditing firm issued a qualified opinion on the Company's 2024 audited financial statements, not an unqualified opinion, due to a limitation in the audit

scope related to two business cooperation contracts: Contract No. 68/HDHTKD dated June 1, 2017 (cooperation in developing the project at the land lot located at 190 Dinh Thon Street, My Dinh 1 Ward, Nam Tu Liem District) and Contract No. 35/2009/HĐHT dated December 25, 2009 (cooperation in developing the project at the land lot located at 118 Nguyen Van Troi Street, Phuong Liet Ward, Thanh Xuan District). As the Company is currently working with its partners and relevant authorities on the implementation of these contracts, the information has not yet been provided to the auditors.

Regarding this matter, the Board of Supervisors has recommended that the Company engage a consulting firm to promptly resolve the issue and protect the Company's rights and interests in accordance with regulations. In addition, the Board of Supervisors has submitted its recommendations on this matter to the BOD and BOM, and requested that the BOD and BOM take appropriate action and implement necessary solutions.

2. Business Performance Results:

The Company closely followed the business targets set by the GMS and focused on implementing solutions to enhance production capacity, improve product quality, reduce costs, and increase operational efficiency.

- Specific business results for the period:

Unit: billion VND

Indicator	Actual 2023	Actual 2024	% Actual 2024 vs. 2023	Plan 2024	% Plan Completion
Revenue	402.741	443.135	110.03%	360.724	122.8%
Earning before tax	14.923	19.418	130.12%	16.117	120.5%
Net Income	11.743	15.246	129.83%	12.668	120.35%

General assessment of business performance during the period:

Revenue and profit increased compared to the previous year. Revenue and profit also exceeded the planned targets.

3. Key Financial Indicators as of December 31:

No.	Indicator	Unit	Year	
			2024	2023
I	**Asset Structure**			
1	Current Assets / Total Assets	%	50.24	57.52
2	Non-current Assets / Total Assets	%	49.76	42.48
II	**Capital Structure**			

1	Liabilities / Total Capital	%	34.32	45.36
2	Owner's Equity / Total Capital	%	65.68	54.64
III	**Liquidity Ratios**			
1	Current Ratio (Current Assets / Short-term Liabilities)	Times	1.46	1.27
2	Quick Ratio ((Cash + Short-term Financial Investments) / Short-term Liabilities)	Times	0.32	0.23
3	Cash Ratio ((Cash + Marketable Securities) / Short-term Liabilities)	Times	0.25	0.16
VI	**Operating Ratios**			
1	Pre-tax Profit / Revenue	%	4.38	3.71
2	After-tax Profit / Revenue	%	3.44	2.92

IV. Recommendations for the Board of Directors and the General Director to continue addressing in the coming period:

- The BOD should consider developing a long-term business strategy to enhance proactiveness in operations.

- Improve and strengthen training and recruitment of qualified and experienced staff, as well as highly skilled technical workers, to support future business and production activities.

- Continue implementing more effective measures to recover due receivables and bad debts.

- Accelerate the implementation of the Pharmaceutical Science and Technology Center and the EU-GMP-standard Pharmaceutical Manufacturing Plant Project to bring it into efficient operation as soon as possible.

V. Work Plan of the Board of Supervisors for 2025:

- Perform inspection and supervision duties over the governance and management activities of the Board of Directors and the Board of Management in accordance with the Company's Charter and the Law on Enterprises;

- Monitor the implementation of resolutions of the General Meeting of Shareholders and resolutions of the Board of Directors in the course of business operations, based on legal regulations and the Company's Charter;

- Review the appropriateness of internal documents and management regulations and their practical application to ensure alignment with the resolutions of the General Meeting of Shareholders. Propose amendments or supplements to internal regulations if deemed necessary;

- Examine accounting records, vouchers, and other Company documents when necessary or upon request of the General Meeting of Shareholders;

- Propose the selection of an independent auditing firm to audit the Company's semi-annual and annual financial statements;

- Review and evaluate financial statements and the Company's business performance on a quarterly, semi-annual, and annual basis;

- Maintain close coordination between the Board of Supervisors, the Board of Directors, the Board of Management, and other relevant units within the Company;

- Participate in major Company activities to stay informed about business operations;

- Attend BOD meetings and quarterly briefings to stay up to date on the Company's situation.

VI. General Assessment of the Activities of the Board of Supervisors:

- The Board of Supervisors performed its functions and duties in accordance with the Company's Charter and the relevant provisions of the Law on Enterprises relating to the Board of Supervisors.

- The Board of Supervisors fulfilled the responsibilities entrusted to it by shareholders, particularly in overseeing business operations and the effective use of capital.

- The performance of the Board of Supervisors during the term was the result of the efforts of each member, as well as the trust, support, and facilitation provided by the Board of Directors, the General Director, departments, and all employees of the Company.

On behalf of the Board of Supervisors, I would like to sincerely thank the General Meeting of Shareholders, the Board of Directors, and the General Director for their trust, support, and cooperation throughout the past year, which enabled the Board of Supervisors to fulfill its duties effectively.

Respectfully!

ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD

Ho Ngoc Tuan

Recipient:
- *Shareholders;*
- *BOD; BOM;*
- *BOS;*
-*Archived: BOS; Secretary; Office.*

CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX
Địa chỉ: 358 Đường Giải Phóng - Quận Thanh Xuân - Hà Nội
Website: http://www.mediplantex.com

No.: 02/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June , 2025

PROPOSAL

Re: Selection of the Independent Auditor for the 2025 Financial Statements

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;*
- *Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company.*

The Board of Supervisors of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

In order to ensure proactivity in selecting an appropriate auditing firm that meets the Company's requirements regarding the timing and quality of auditing services for the financial statements of the fiscal year 2025, the Board of Supervisors respectfully proposes that the General Meeting of Shareholders consider and approve the following contents:

1. Approval of criteria for selecting the independent auditing firm for the 2025 Financial statements:

- The auditing firm must be an independent audit enterprise included in the list of entities eligible to provide audit services as announced by the Ministry of Finance at the time of selection. It must fully meet all professional standards and conditions, possess a team of qualified auditors, and be approved by the State Securities Commission to audit public interest entities operating in the securities sector in 2025.
- The firm must have a strong reputation and extensive experience in the field.
- The firm must not have any conflicts of interest in connection with auditing the Corporation's financial statements.
- The proposed audit fee must be competitive and appropriate to the content, scope, and timeline of the audit engagement.

2. Approval of the following list of auditing firms proposed to conduct the audit of the financial statements for the fiscal year 2025 and the review of the quarterly and semi-annual financial statements (if required by State regulatory authorities) for Mediplantex National Pharmaceutical Joint Stock Company, including:

1.1. KPMG Company Limited;

1.2. AASC Auditing Firm Company Limited;

1.3. PWC (Vietnam) Company Limited;

1.4. Viet Nam Auditing & Evaluation Company Limited;

1.5. An Viet Auditing Company Limited.

1.6. Other audit firms included in the list of audit companies approved by the State Securities Commission to audit public interest entities in the securities sector for the year 2025.

3. Estimated auditing fee: From VND 200,000,000 to VND 500,000,000.
4. The Board of Supervisors respectfully submits to the General Meeting of Shareholders a proposal to authorize the Board of Directors to select one of the aforementioned auditing firms to conduct the audit and review of the 2025 financial statements. In the event that the selected auditing firm is unable to continue the audit and review, or if the Board of Directors deems that the selected firm cannot ensure timely issuance of the reports, the Board of Supervisors seeks the General Meeting's authorization for the Board of Directors to change the auditing firm, provided that the replacement meets the required criteria and is selected from the list previously approved by the General Meeting of Shareholders. Any change of auditing firm will be disclosed as an extraordinary information disclosure in accordance with the prevailing laws and regulations on information disclosure in the securities market.
5. The Board of Directors authorizes the General Director / Legal Representative to sign the audit contract with the selected auditing firm.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Recipients:
- *Company Shareholders;*
- *BOD; BOM;*
- *BOS;*
- *Archived: Company Secretary.*

ON BEHALF OF
THE BOARD OF SUPERVISORS
HEAD

Ho Ngoc Tuan

CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX
Địa chỉ: 358 Đường Giải Phóng - Quận Thanh Xuân - Hà Nội
Website: http://www.mediplantex.com

No.: 03/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

Re: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;*
- *The Law on Securities No. 54/2019/QH14 was passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and came into effect on January 1, 2021; as amended by Law No. 56/2024/QH15, which was adopted by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024.*
- *The Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;*
- *The 2024 business and production results and the implementation plan for 2025.*

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

I. PROFIT DISTRIBUTION PLAN FOR 2024:

Indicators	Percentage (%)	Year 2024 (Unit: VND)
1. Profit before tax in 2024		**19,418,107,894**

2. Corporate income tax payable in 2024		**4,171,341,682**
3. Profit after tax in 2024		**15,246,766,212**
4. Profit distribution in 2024		**15,246,766,212**
4.1. Bonus allocation to the Board of Management		246,584,856
Bonus for Achievement of Profit Target	1%	*128,938,363*
Additional Bonus: 5% of the value of profit exceeding the planned target		*117,646,493*
4.2. Bonus allocation to the Board of Directors and the Board of Supervisors		246,584,856
Bonus for achievement of profit target	1%	*128,938,363*
Additional bonus: 5% of the value of profit exceeding the planned target		*117,646,493*
4.3. Allocation to the Development Investment Fund	0%	
4.4. Remaining profit for dividend distribution		14,753,596,500
5. Retained earnings from previous years		**503,923,388**
6. Total profit for dividend distribution up to the end of 2024		**15,257,519,888**
7. Proposed dividend distribution	12% of charter capital	**14,892,000,000**
8. Retained earnings for 2025		**365,519,888**

II. DIVIDEND PAYOUT RATIO FOR 2024

The Board of Directors respectfully submits to the General Meeting of Shareholders for approval the proposal to distribute dividends in cash and to authorize the Board of Directors to determine and implement the timing of the dividend payment. The proposed dividend payment plan is as follows:

- **Dividend payout ratio: 12%**
- **Total dividend payment amount: 14,892,000,000 VND**

III. PROPOSAL FOR 2025

- Based on the 2025 business and production plan of Mediplantex National Pharmaceutical

Joint Stock Company, the Board of Directors proposes the allocation of bonuses and the dividend payout rate for 2025 as follows:

Projected for 2025	Percentage %	Amount VND
I. Profit Before Tax 2025		**12,903,687,571**
II. Profit After Tax 2025		**10,322,950,057**
1. Allocation for bonus to the Board of Management	1%	103,229,501
2. Allocation for bonus to the Board of Directors and the Board of Supervisors	1%	103,229,501
3. Allocation to the Development Investment Fund	0	0
4. Remaining profit for dividend distribution	8% of charter capital	9,928,000,000
5. Retained earnings for 2026		188,491,056

- The allocation of bonuses to the Board of Management and to the Board of Directors and the Board of Supervisors at the above-mentioned rates shall only be implemented if the profit after tax in 2025 reaches 90% to 100% of the 2025 approved plan.
- In the event that the 2025 performance exceeds the plan approved by the General Meeting of Shareholders:

  + Additional bonus for the Board of Management at the rate of 05% of the excess amount over the plan.

  + Additional bonus for the Board of Directors and the Board of Supervisors at the rate of 05% of the excess amount over the plan.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:
- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.

ON BEHALF OF
THE BOARD OF DIRECTORS

Thai Khac Minh

No.:05/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June , 2025

PROPOSAL

Re: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term

To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

- Based on the letter of resignation submitted by the member of the Board of Directors to the Board of Directors;

The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval of the following matters:

1. Based on the resignation letter submitted by a member of the Board of Directors, the Board respectfully proposes that the General Meeting of Shareholders approve the dismissal of:

Mr. Tran Xuan Dinh - Member of the Board of Directors for the 2024–2029 term

Reason for dismissal Voluntary resignation

Upon the approval of Mr. Tran Xuan Dinh's resignation, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the 2024–2029 term will consist of only 03 members, thereby failing to meet the structural requirements of the Board of Directors as prescribed by the Company's Charter. Accordingly, the Board of Directors deems it necessary to propose the election of an additional member to the Board of Directors for the 2024–2029 term.

2. The Board of Directors respectfully proposes to the General Meeting of Shareholders of the Company for consideration and approval the election of additional members to the Board of Directors for the 2024–2029 term, as follows:

- Number of additional members to be elected to the BOD: 02 member

- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.

- Number of candidates: Unlimited.

Based on the nomination and self-nomination results submitted by shareholders and groups of shareholders in accordance with the Company's Charter, and considering the competence, qualifications, and reputation of the nominees, and in compliance with the criteria for BOD members as prescribed by the Company's Regulations on the Operation of the BOD and applicable laws, the BOD respectfully proposes to the General Meeting of Shareholders for approval the List of Candidates for the election of two (02) additional member of the BOD for the remainder of the 2024 – 2029 term as follows:

- Ms: Nguyen Ngoc Xuan Trang Candidate for the Board of Directors
- Ms: Tran Nguyen Hoàng Phuc Candidate for the Board of Directors

Curricula Vitae of the Candidates Attached to This Proposal.

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:
- Company Shareholders;
- BOD; BOS;
- Archived: Company Secretary.

ON BEHALF OF
THE BOARD OF DIRECTORS



Thai Khac Minh



SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

CURRICULUM VITAE

(For candidates nominated/elected to the Board of Directors)

1. Full name: Tran Nguyen Hoang Phuc Gender: Female

2 Date of birth: 02/12/1991 Place of birth: Ho Chi Minh City

3. Nationality: Vietnamese

4. ID/Passport number: 079191020545 Date of issue: April 24, 2021

Place of issue: Police Department for Administrative Management of Social Order

5. Permanent residence: 506/15/34, February 3 Street, District 10, Ho Chi Minh City

6. Telephone number: …… Email: ……

7. Academic qualifications: 12/12

8. Professional qualifications: Bachelor's degree in Biochemistry

9. Work experience

Period	Work experience, profession, and positions held (what was done, where it was done)	Note
01/07/2024- 29/07/2024	Assistant to the General Director, Mediplantex National Pharmaceutical Joint Stock Company	
01/08/2024 - present	Head of Legal and Inspection Department, Mediplantex National Pharmaceutical Joint Stock Company	
01/11/2024 - present	Head of Organization and Administration Department, Mediplantex National Pharmaceutical Joint Stock Company	

10. Current position at Mediplantex National Pharmaceutical Joint Stock Company (if any):

Head of Organization and Administration Department cum Head of Legal Department

11. Current position at other entities or organizations: None

Company name	Address	Business Registration Certificate	Date/Place of Issue	Position	Ownership Ratio / Capital Contribution

12. The number of shares held and represented (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: 2,761,900 shares, accounting for 22.26% of the charter capital. Of which:

+ Shares held as representative (on behalf of state/strategic shareholder/other organization): ……. shares

+ The number of shares personally owned: 2,761,900 shares

13. Other commitments to hold (if any): .....

14. List of related persons to the applicant *:

No.	Name of individual/organization	ID card number/Citizen ID/Passport(for individuals) or Business Registration Certificate number/Operating License or equivalent legal document (for organizations)	Date of issue	Place of issue	Number of shares held, ownership percentage of the company's charter capital (if any)	Relationship
1	Tran Hoang Dung	087060006964	10/07/2021	Police Department for Administrative Management of Social Order	1,000,000	Father
2	Nguyen Ngoc Xuan Trang	079166010931	29/04/2021	Police Department for Administrative Management of Social Order	3,543,044	Mother
3	Vo Thi Thuy Phuong Loan	064168000050	11/08/2021	Police Department for Administrative Management of Social Order		Mother-in-law
4	Tran Xuan Dinh	079091010916	23/09/2022	Police Department for Administrative Management of Social Order		Husband
5	Tran Nguyen Hoang An	079094025506	22/11/2021	Police Department for Administrative Management of Social Order	20,000	Younger brother
6	Tran Nguyen Hoang Hy	079305028978	15/03/2021	Police Department for Administrative Management of Social Order	47,000	Younger sister

7	Tran Nguyen Hoang An	012819160	03/07/2014	Ho Chi Minh city's public security	87,500	Older sister

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

16. Interests in conflict with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

I hereby affirm that the above statements are completely true and accurate. If any information is found to be false, I fully accept responsibility before the law.

CONFIRMATION OF THE LOCAL AUTHORITIES OR WORKPLACE (IF ANY)

DECLARANT
(Signature and full name)

Marymount University

Arlington Virginia

The Board of Trustees of Marymount University upon the recommendation of the Faculty hereby confers upon

Phuc Nguyen Hoang Tran

the degree of

Bachelor of Science

with all the rights, privileges and honors thereunto appertaining.
In Witness Whereof we have hereunto affixed our signatures and the Seal of the University at Arlington, Virginia
Nineteenth Day of December, Two Thousand Fifteen

Chairman, Board of Trustees

MARYMOUNT UNIVERSITY
TUA LUCE DIRIGE
1950
ARLINGTON • VIRGINIA

President

Vice President for Academic Affairs



THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

CURRICULUM VITAE

(For candidates nominated/elected to the Board of Directors Directors)

1. Full name: Nguyen Ngoc Xuan Trang — Gender: Female
2. Date of birth: 18/05/1966 — Nơi sinh: Long An.
3. Nationality: Vietnam
4. ID Card/Citizen ID/Passport: 079166010931 — Date of issue: 29/04/2021

Place of issue: Police Department on Administrative Management of Social Order

5. Permanent residence: 506/15/34, 3 Thang 2 Street, District 10, Ho Chi Minh City
6. Telephone number: ……..…..…Email:……...
7. Academic qualifications:12/12
8. Professional qualifications:
9. Work experience:

Period	Employment History, Profession, and Positions Held (what, where)	Note
January 2010 – present	Director of An Hy Pharmaceutical Company Limited	

10. Current Position at Mediplantex National Pharmaceutical Joint Stock Company (if any): None
11. Current Positions Held at Other Organizations:

Company Name	Address	Business Registration Certificate	Date/Place of Issuance	Position	Ownership Ratio / Capital Contribution
An Hy Pharmaceutical Company Limited	506/15/34, 3/2 Street, Ward 14, District 10, HCM	0309738339	22/05/2017, Department of Planning and Investment of HCMC	Director	

12 Number of shares held (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: 3,543,044 shares, accounting for 28.5% of the charter capital, including:

+ Shares held as representative (on behalf of state/strategic shareholder/other organization): ……. shares

+ The number of shares personally owned: 3,543,044 shares

13 Other commitments to hold (if any): ……

14 List of related persons to the applicant *:

No.	Name of individual/organization	ID Number of the Shareholder / Citizen ID	Date of Issue	Place of Issue	Number of Shares Held, Ownership Percentage of the	Relationship to the Declarant

					Company's Charter Capital	
1	Tran Hoang Thuong	340656440	28/06/2002	Dong Thap province's public security		Father-in-law
2	Luong Thi Ngoc Xoan	340203158	13/04/1999	Dong Thap province's public security		Mother-in-law
3	Tran Hoang Dung	087060006964	10/07/2021	Police Department for Administrative Management of Social Order	1,000,000	Husband
4	Tran Nguyen Hoang Phuc	079191020545	24/04/2021	Police Department for Administrative Management of Social Order	2,761,900	Daughter
5	Tran Xuan Dinh	079091010916	23/09/2022	Police Department for Administrative Management of Social Order	0	Son-in-law
6	Tran Nguyen Hoang An	079094025506	22/11/2021	Police Department for Administrative Management of Social Order	20,000	Son
7	Tran Nguyen Hoang Hy	079305028978	15/03/2021	Police Department for Administrative Management of Social Order	47,000	Daughter
8	Tran Nguyen Hoang An	012819160	03/07/2014	Ho Chi Minh city's public security	87,500	Daughter
9	Nguyen Ngoc Minh Trang				0	Younger Sister
10	Nguyen Hong Hien Nhan				0	Younger Brother
11	Nguyen Ngoc Thao Trang				0	Younger Sister

12	An Hy Pharmaceutical Company Limited	0309738339	22/05/2017	Department of Planning and Investment of Ho Chi Minh City	0	Director

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

16. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any): None

I hereby affirm that the above statements are completely true and accurate. If any information is found to be false, I fully accept responsibility before the law.

CONFIRMATION OF THE LOCAL AUTHORITIES OR WORKPLACE (IF ANY)

DECLARANT
(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025

VOTING BALLOT
VOTER ID: .....

Full name: .....
Number of votes owned: ..... votes
Number of votes authorized: .....votes
Total number of votes represented: ……votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Approval of Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025	☐	☐	☐
Content 02: Approval of Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025	☐	☐	☐
Content 03: Approval of Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025	☐	☐	☐
Content 04: Approval of the audited financial statements for 2024	☐	☐	☐
Content 05: Approval of the selection of an independent auditing firm for the 2025 financial statements	☐	☐	☐
Content 06: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025	☐	☐	☐
Content 07: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025	☐	☐	☐
Content 08: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term	☐	☐	☐

Guide:

Shareholders tick (X) in one of 3 boxes:
Approve/Disapprove/Abstain each Proposal.

June 30th 2025
VOTER
(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025

VOTE ON THE BOARD OF DIRECTORS
VOTER ID: .....

Full name: .....
Number of votes owned: ..... votes
Number of votes authorized: ..... votes
Total number of votes represented: ……votes
Total number of voting rights..... **voting rights**

I hereby agree to cast the votes for the chosen Additional Member of the Board of Directors

No	Full Name	Cumulative voting	Number of votes
1	NGUYEN NGOC XUAN TRANG	☐	
2	TRAN NGUYEN HOANG PHUC	☐	

Guide:

1. The maximum number of candidates that delegates are eligible to elect is equal to the number of candidates needed to elect (01 member)
2. If accumulative elect the entire elect for one or several candidates, delegates mark in **"Cumulative voting"** of the corresponding candidates.
3. If the number of elections is uneven for many candidates, the delegate must specify the number of elections in the **"Number of votes"** of the corresponding candidates.

June 30th, 2025
VOTER
(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 01/2025/NQ-DHDCD/MED

Hanoi, June 30, 2025

RESOLUTION
2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022;*
- *The Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;*
- *The Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Minutes of the 2025 Annual General Meeting of Shareholders No. ... dated June 30, 2025;*
- *The Vote Counting Minutes of the 2024 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company dated June 30, 2025.*

The 2025 Annual General Meeting of Shareholders ("AGM") of Mediplantex National Pharmaceutical Joint Stock Company, convened at Guest House T99, Military Zone of the Capital – No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi, on June 30, 2025, hereby adopts the following Resolution:

RESOLUTION

Article 1. Approval of the following reports**:**

- Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025;
- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;

Article 2. Approval of the audited financial statements for 2024 *(Pursuant to Proposal No. 01/2025/TTr-DHDCD dated June 9, 2025).*

Article 3. Approval of the selection of an independent auditing firm for the 2025 financial statements *(Pursuant to Proposal No. 02/2025/TTr-DHDCD dated June 9, 2025).*

Article 4. Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025 *(Pursuant to Proposal No. 03/2025/TTr-DHDCD dated June 9, 2025).*

Article 5. Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 *(Pursuant to Proposal No. 04/2025/TTr-DHDCD dated June 9, 2025).*

Article 6. Approval of the Dismissal for the Additional Members of the Board of Directors for the 2024 – 2029 Term *(Pursuant to Proposal No. 05/2025/TTr-DHDCD dated June 9, 2025)* for Mr. Tran Xuan Dinh, effective from the date on which it is approved by the General Meeting of Shareholders.

Article 7. Approval of the Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term *(Pursuant to Proposal No No. 05/2025/TTr-DHDCD dated June 9, 2025)* for:

1. Mr./Ms.:
   Year of birth:
   Professional qualifications:
2. Mr./Ms.:
   Year of birth:
   Professional qualifications:

This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

ON BEHALF OF THE 2025 GENERAL MEETING OF SHAREHOLDERS
CHAIRPERSON